research published 2023-05-01 · by Adegunsoye A, Strykowski R

Immunology and allergy clinics of North America · 2023 May

PubMed #37055085

Abstract

Idiopathic pulmonary fibrosis (IPF), a common interstitial lung disease (ILD), is a chronic, progressive fibrosing interstitial pneumonia, with an unknown cause. IPF has been linked to several genetic and environmental risk factors. Disease progression is common and associated with worse outcomes. Management often encompasses pharmacotherapy, supportive interventions, addressing comorbidities when present, and treating hypoxia with ambulatory O2. Consideration for antifibrotic therapy and lung transplantation evaluation should occur early. Patients with ILD other than IPF, and who have radiological evidence of pulmonary fibrosis, may have progressive pulmonary fibrosis.

Neurotransmitters

None linked yet.

Related

Community votes: 0

Ratings (0): Breadth — · Depth — · Enjoyment — · Usefulness —

Community

Log in to rate and share your notes.

No contributions yet.